The Türkiye Heart Failure Registry
ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBaskent University
About this trial
A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The only inclusion criterion for the Türkiye Heart Failure (TURK-HF) registry is the presence of heart failure, as determined by an investigator, and the only exclusion criterion is age \<18 years. All patients will be eligible for enrollment regardless of their ejection fraction and whether they have pre-existing chronic or de novo heart failure. All patients will be enrolled in the study, regardless of their clinical status. This encompasses both those presenting for a non-urgent outpatient visit with stable signs and symptoms and those requiring urgent care with worsening of heart failure. Worsening heart failure is defined as worsening symptoms and signs of heart failure in patients with pre-existing heart failure, requiring hospitalization and/or intravenous diuretic therapy. All study participants must provide written informed consent.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Heart failure medication
Other interventionTreated with optimal guideline-directed medical therapy
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Heart failure hospitalization
Time frame
From enrollment to the end of follow-up period at 12 months2
Cardiovascular mortality
Time frame
From enrollment to the end of follow-up period at 12 months3
Composite of heart failure hospitalization and cardiovascular mortality
Time frame
From enrollment to the end of follow-up period at 12 monthsSecondary outcomes
1
All-cause mortality
Time frame
From enrollment to the end of follow-up period at 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov